Poster Presentation



Publications
Poster Presentation
Block-Removed Immunoglobulin Technology (BRITE) to enhance rituximab effector function by counteracting CA125-mediated immunosuppression
Publication
Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding
Publication
Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagement
Poster Presentation
Development of NAV-005, a humoral immuno-suppressor antagonist for the treatment of CA125-expressing cancers.
Publication